Dongying Tiandong Pharmaceutical Co., Ltd. was established in 1992 and is affiliated to Shandong Haike Chemical Group. It specializes in the research, development, production and sales of heparin and low molecular weight heparin series anticoagulant drugs. The company's fixed assets are 350 million yuan. The main products include heparin sodium API, enoxaparin sodium API, natriheparin calcium API and enoxaparin sodium injection and other products, and the products are exported to more than 40 countries and regions around the world.
The company is committed to providing customers with high-quality products and services, and continuously improving the production quality management system, and has successively passed a series of certifications from domestic and international pharmaceutical authorities, including China GMP certification, European Union COS certification, US FDA certification and Sweden, Mexico, Turkey and other official certifications.
The company has been focusing on the research and development of blood system drugs for many years, and has established a stable industry-university-research and use cooperative relationship with the National Sugar Engineering Technology Research Center. The company has established research and development platforms such as post-doctoral research workstations, Shandong Provincial Biochemical Drug Engineering Laboratory, and provincial-level enterprise technology centers, and has successively undertaken research projects such as national major new drug creation, scientific and technological support plans, torch plans, and key new products, and has applied for more than 20 patent protections.
The company has built a small-capacity injection workshop, and started the construction of the second-phase projects such as a solid preparation workshop, accelerating the upgrade of the industrial chain from APIs to preparations. Tiandong is committed to becoming a comprehensive pharmaceutical enterprise driven by innovation and research.